Loading cancer entity…
Loading cancer entity…
Clinical trials
24 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03180502 | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma | active not recruiting | Phase 2 | 120 | NRG OncologyOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04623931 | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02530320 | Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved | completed | Phase 2 | 34 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Nov 22, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 28, 2026source: clinicaltrials
| NCT00303849 |
| Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors |
| completed |
| Phase 1 / Phase 2 |
| 33 |
| OHSU Knight Cancer InstituteOTHER |
| 1 |
| Mar 17, 2022 |
| clinicaltrials |
| NCT01635283 | Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma | completed | Phase 2 | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT02209428 | A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas | unknown | Phase 2 | 54 | Huashan HospitalOTHER | 1 | Feb 21, 2019 | clinicaltrials |
| NCT00362570 | Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | completed | Phase 2 | 1 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00389090 | A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma | terminated | Phase 2 | 32 | Keryx / AOI Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 9, 2012 | clinicaltrials |